Index Ventures

Nexthink is a global leader in digital experience management. The company's product allows enterprises to create highly productive digital workplaces for their employees by delivering optimal end-user experience. Through a unique combination of real-time analytics, automation and employee feedback across all endpoints, Nexthink helps IT teams meet the needs of the modern digital workplace.

Nexthink is a global leader in digital experience management. The company's product allows enterprises to create highly productive digital workplaces for their employees by delivering optimal end-user experience. Through a unique combination of real-time analytics, automation and employee feedback across all endpoints, Nexthink helps IT teams meet the needs of the modern digital workplace.

Mind-NRG, based out of Switzerland, is devoted to the development of NRG-101 in psychiatric and neurologic diseases. NRG-101 is a neurotrophic factor with disease modifying potential that naturally crosses the blood - brain barrier through a receptor-mediated transport to reach its target in the brain. NRG-101 will be developed to treat disorders such as Parkinson's disease, Alzheimer's disease and schizophrenia. Mind-NRG will initially focus on conducting in vitro and in vivo experiments to further explore the mechanism of action of the peptide and to assess the activity of NRG-101 in a variety of relevant disease models.

Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & Associes Consultants SA) to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization. Oncoethix founders have an unsurpassed track record in identifying and bringing oncology leads to global markets. Dr. Cvitkovic, Chief Scientific Officer for Oncoethix, led the clinical development of single agent and combination regimens for cisplatin, vindesine, bleomycin, navelbine, and, more recently, irinotecan, oxaliplatin, docetaxel, and trabectedin, first as an academic investigator and then through a specialized oncology clinical research organization. Prior to founding Oncoethix and assuming responsibilities as Chief Operating Officer, Dr. Noel had co-founded another oncology drug development company which in-licensed oxaliplatin as its first portfolio product and subsequently identified, evaluated, and in-licensed novel agents for several clients. Additionally, Dr. Noel has developed expedited registration strategies for many cancer drugs and registration files for a few of these. Dr. Herait managed clinical development of irinotecan, from Phase 1 through Phase 3, while at Rhone Poulenc Rorer and subsequently, as a consultant, managed clinical studies for several novel cancer drugs. Since its founding, Oncoethix has in-licensed three promising cancer drug candidates, each a first-in-class agent to a novel target or with a novel mode of action. Currently, two portfolio compounds are in clinical development. Oncoethix was launched with an initial financing of 1.30 million Swiss francs from the founders to finance portfolio development. In December 2009, the company closed a Series A financing of 3.7 million Swiss francs with leading venture capital firms Index Ventures and Endeavour Vision.

HouseTrip is one of Europe's largest holiday rental websites, with over 300,000 properties to choose from in thousands of destinations worldwide. HouseTrip makes it easy for guests and homeowners to find, book and list holiday rental properties securely online. Founded by husband and wife team Arnaud Bertrand and Junjun Chen, HouseTrip went live in January 2010 and has since seen over 6,000,000 nights booked. There are HouseTrip offices in the UK (London), Switzerland (Lausanne) and Portugal (Lisbon.) HouseTrip recently received $40 million in Series C funding led by Accel Partners with existing investors Balderton Capital and Index Ventures.

Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & Associes Consultants SA) to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization. Oncoethix founders have an unsurpassed track record in identifying and bringing oncology leads to global markets. Dr. Cvitkovic, Chief Scientific Officer for Oncoethix, led the clinical development of single agent and combination regimens for cisplatin, vindesine, bleomycin, navelbine, and, more recently, irinotecan, oxaliplatin, docetaxel, and trabectedin, first as an academic investigator and then through a specialized oncology clinical research organization. Prior to founding Oncoethix and assuming responsibilities as Chief Operating Officer, Dr. Noel had co-founded another oncology drug development company which in-licensed oxaliplatin as its first portfolio product and subsequently identified, evaluated, and in-licensed novel agents for several clients. Additionally, Dr. Noel has developed expedited registration strategies for many cancer drugs and registration files for a few of these. Dr. Herait managed clinical development of irinotecan, from Phase 1 through Phase 3, while at Rhone Poulenc Rorer and subsequently, as a consultant, managed clinical studies for several novel cancer drugs. Since its founding, Oncoethix has in-licensed three promising cancer drug candidates, each a first-in-class agent to a novel target or with a novel mode of action. Currently, two portfolio compounds are in clinical development. Oncoethix was launched with an initial financing of 1.30 million Swiss francs from the founders to finance portfolio development. In December 2009, the company closed a Series A financing of 3.7 million Swiss francs with leading venture capital firms Index Ventures and Endeavour Vision.

HouseTrip is one of Europe's largest holiday rental websites, with over 300,000 properties to choose from in thousands of destinations worldwide. HouseTrip makes it easy for guests and homeowners to find, book and list holiday rental properties securely online. Founded by husband and wife team Arnaud Bertrand and Junjun Chen, HouseTrip went live in January 2010 and has since seen over 6,000,000 nights booked. There are HouseTrip offices in the UK (London), Switzerland (Lausanne) and Portugal (Lisbon.) HouseTrip recently received $40 million in Series C funding led by Accel Partners with existing investors Balderton Capital and Index Ventures.

HouseTrip is one of Europe's largest holiday rental websites, with over 300,000 properties to choose from in thousands of destinations worldwide. HouseTrip makes it easy for guests and homeowners to find, book and list holiday rental properties securely online. Founded by husband and wife team Arnaud Bertrand and Junjun Chen, HouseTrip went live in January 2010 and has since seen over 6,000,000 nights booked. There are HouseTrip offices in the UK (London), Switzerland (Lausanne) and Portugal (Lisbon.) HouseTrip recently received $40 million in Series C funding led by Accel Partners with existing investors Balderton Capital and Index Ventures.

Mind-NRG, based out of Switzerland, is devoted to the development of NRG-101 in psychiatric and neurologic diseases. NRG-101 is a neurotrophic factor with disease modifying potential that naturally crosses the blood - brain barrier through a receptor-mediated transport to reach its target in the brain. NRG-101 will be developed to treat disorders such as Parkinson's disease, Alzheimer's disease and schizophrenia. Mind-NRG will initially focus on conducting in vitro and in vivo experiments to further explore the mechanism of action of the peptide and to assess the activity of NRG-101 in a variety of relevant disease models.

Mind-NRG, based out of Switzerland, is devoted to the development of NRG-101 in psychiatric and neurologic diseases. NRG-101 is a neurotrophic factor with disease modifying potential that naturally crosses the blood - brain barrier through a receptor-mediated transport to reach its target in the brain. NRG-101 will be developed to treat disorders such as Parkinson's disease, Alzheimer's disease and schizophrenia. Mind-NRG will initially focus on conducting in vitro and in vivo experiments to further explore the mechanism of action of the peptide and to assess the activity of NRG-101 in a variety of relevant disease models.

GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections.

The matchmaking service be2 was launched in April 2004 with its German website www.be2.de. With a clear focus on internationalization, be2 introduced its service to other countries and today is represented in an impressive 37 countries on six continents. This makes be2 the largest online matchmaking service by unique visitors in Europe and the world's fastest growing one (Nielsen Net Ratings, April 2008, ComScore March 2008). be2's management team of five boasts 55 years of collective experience in the online industry and in nurturing start-ups into profitable firms. It's wide-ranging expertise consists of top executive positions with Bertelsmann, Lycos, Scout 24 and management consulting companies such as Roland Berger. From the outset be2 has focused its activities on establishing an internationally structured organization. Today be2 employs 170 people from 43 nationalities with headquarters in Zurich, Switzerland and Grevenmacher, Luxembourg.

Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and significantly improve the management of serious diseases. They are developing a powerful new class of potent, specific and versatile small protein therapies called DARPin® therapeutics.

GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections.

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators for neurological disorders. Its modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecules or biological drugs. Its allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.

GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections.

SpinX develops and commercializes a programmable lab-on-a-chip platform for applications that ranges from drug discovery to consumer diagnostics. Its products include SpinX Lab, a system to transition from low volume microplate assays to an automated bench-top technology for assays in nanoliter volumes; and workflow, an assay preparation for a panel of enzymatic assays. Bart Van de Vyver and Piero Zucchelli founded SpinX in 2003. It has its headquarters in Geneva in Switzerland.

Innovative Silicon was founded to develop and commercialise Floating Body effect memory for SoC/MPU products used in diverse applications including handheld computers, games consoles, cellular communications devices, cameras. The company closed its first round of VC funding in 2003, completed its first 90nm megabit Z-RAM memory design in 2004 and its first 65nm designs in 2005. The company was founded in 2002 and is headquartered in Santa Clara, California with additional offices in Lausanne, Switzerland; and Yokohama, Japan.

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators for neurological disorders. Its modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecules or biological drugs. Its allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.

Innovative Silicon was founded to develop and commercialise Floating Body effect memory for SoC/MPU products used in diverse applications including handheld computers, games consoles, cellular communications devices, cameras. The company closed its first round of VC funding in 2003, completed its first 90nm megabit Z-RAM memory design in 2004 and its first 65nm designs in 2005. The company was founded in 2002 and is headquartered in Santa Clara, California with additional offices in Lausanne, Switzerland; and Yokohama, Japan.

Kimotion provides front-to-back analog design software, including modeling, sizing and layout tools, addressing high-complexity analog functional blocks. Our software helps circuit designers quickly size and layout complex designs containing thousands of transistors, without compromising design performance. Kimotion is a technology spin-off of the Katholieke Universiteit Leuven, with venture capital funding from Index Ventures and Innovacom. The company has offices near Geneva, Switzerland and Leuven, Belgium.

BeamExpress, a spin-off from BeamExpress Inc, is a privately held company working in cooperation with EPFL (The Swiss Federal Institute of Technology) to develop long wavelength VCSELs (Vertical Cavity Surface Emitting Laser) for high-speed optical communications as well as gas spectrometry. BeamExpress is using a unique proprietary fabrication technique – the localized wafer fusion process - developed by the members of the founding team, which provides high performance 1310nm devices up to 10Gb/s but also VCSELs laser sources with high precision wavelengths ranging from 1200nm up to 2000nm for CWDM application and for the gas sensing industry. BeamExpress is a fabless company, outsourcing its production to leading European partners.

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators for neurological disorders. Its modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecules or biological drugs. Its allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.

BeamExpress, a spin-off from BeamExpress Inc, is a privately held company working in cooperation with EPFL (The Swiss Federal Institute of Technology) to develop long wavelength VCSELs (Vertical Cavity Surface Emitting Laser) for high-speed optical communications as well as gas spectrometry. BeamExpress is using a unique proprietary fabrication technique – the localized wafer fusion process - developed by the members of the founding team, which provides high performance 1310nm devices up to 10Gb/s but also VCSELs laser sources with high precision wavelengths ranging from 1200nm up to 2000nm for CWDM application and for the gas sensing industry. BeamExpress is a fabless company, outsourcing its production to leading European partners.